Transaction · 0001193125-26-383618

Aslan Fred

Aslan Fred, CEO, reported an open-market or private sale at Artiva Biotherapeutics, Inc. involving 61888.000000 shares for an estimated $690391.58. Reported holdings after the transaction were 1473194.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SCEO
ARTVArtiva Biotherapeutics, Inc.
Filing timeSep 04
Trade dateSep 03, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$11.12
Pre-filing
1mo ago -0.4%1w ago +7.4%1d ago +1.7%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

ARTV price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ARTV since 2026-09-04Filed today · pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-383618
Common Stock
Transaction date
Sep 03, 2026
Filed Sep 04, 2026, 08:02 PM · 1d delay
Shares
61.8k sh
$1.11k per share
Estimated value
-$69.0M
Computed from shares × price
Holdings after
1.47M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership
+10score
Filing-only score

+10

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold…

  2. F2

    The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0270 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder…

Original filing · 0001193125-26-383618
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ARTV